Published in Genes Dis on April 27, 2017
A simplified system for generating recombinant adenoviruses. Proc Natl Acad Sci U S A (1998) 24.58
LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science (2003) 19.77
Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet (2008) 19.65
Development and applications of CRISPR-Cas9 for genome engineering. Cell (2014) 13.50
HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis. Lancet (2008) 8.37
Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy. Proc Natl Acad Sci U S A (1994) 8.13
Progress and problems with the use of viral vectors for gene therapy. Nat Rev Genet (2003) 6.95
Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes. Nat Biotechnol (2008) 6.82
Construction of adenovirus vectors through Cre-lox recombination. J Virol (1997) 6.72
Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy. N Engl J Med (2002) 6.25
Immune control of an SIV challenge by a T-cell-based vaccine in rhesus monkeys. Nature (2008) 6.17
Gene therapy -- promises, problems and prospects. Nature (1997) 6.02
Recombinant human bone morphogenetic protein-2 for treatment of open tibial fractures: a prospective, controlled, randomized study of four hundred and fifty patients. J Bone Joint Surg Am (2002) 5.95
Persistence of Ebola Virus in Ocular Fluid during Convalescence. N Engl J Med (2015) 5.92
In vivo transfer of the human cystic fibrosis transmembrane conductance regulator gene to the airway epithelium. Cell (1992) 5.85
Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector. Nat Genet (2000) 5.80
Oncolytic virotherapy. Nat Biotechnol (2012) 5.79
Efficient generation of recombinant adenovirus vectors by homologous recombination in Escherichia coli. J Virol (1996) 5.71
Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer. Mol Genet Metab (2003) 5.27
A protocol for rapid generation of recombinant adenoviruses using the AdEasy system. Nat Protoc (2007) 5.15
Induction of broadly neutralizing H1N1 influenza antibodies by vaccination. Science (2010) 5.13
Osteogenic protein-1 (bone morphogenetic protein-7) in the treatment of tibial nonunions. J Bone Joint Surg Am (2001) 5.13
Synthetic DNA delivery systems. Nat Biotechnol (2000) 4.82
Repeat-induced gene silencing in mammals. Nat Genet (1998) 4.74
Comparative seroprevalence and immunogenicity of six rare serotype recombinant adenovirus vaccine vectors from subgroups B and D. J Virol (2007) 4.54
Self-complementary recombinant adeno-associated virus (scAAV) vectors promote efficient transduction independently of DNA synthesis. Gene Ther (2001) 4.35
Gene therapy death prompts review of adenovirus vector. Science (1999) 4.33
a controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat Med (2000) 4.15
Viral vectors for gene therapy: the art of turning infectious agents into vehicles of therapeutics. Nat Med (2001) 4.02
A helper-dependent adenovirus vector system: removal of helper virus by Cre-mediated excision of the viral packaging signal. Proc Natl Acad Sci U S A (1996) 3.89
Clinical trial results with oncolytic virotherapy: a century of promise, a decade of progress. Nat Clin Pract Oncol (2007) 3.86
Engineering targeted viral vectors for gene therapy. Nat Rev Genet (2007) 3.69
Efficacy of gene therapy for X-linked severe combined immunodeficiency. N Engl J Med (2010) 3.54
Ebola RNA Persistence in Semen of Ebola Virus Disease Survivors - Preliminary Report. N Engl J Med (2015) 3.47
Osteogenic activity of the fourteen types of human bone morphogenetic proteins (BMPs). J Bone Joint Surg Am (2003) 3.36
Generation of adenovirus by transfection of plasmids. Nucleic Acids Res (1983) 3.33
Intravenous administration of self-complementary AAV9 enables transgene delivery to adult motor neurons. Mol Ther (2009) 3.33
Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine. N Engl J Med (2013) 3.24
Efficient manipulation of the human adenovirus genome as an infectious yeast artificial chromosome clone. Proc Natl Acad Sci U S A (1994) 2.92
Packaging capacity and stability of human adenovirus type 5 vectors. J Virol (1993) 2.76
Use of recombinant human bone morphogenetic protein-2 to achieve posterolateral lumbar spine fusion in humans: a prospective, randomized clinical pilot trial: 2002 Volvo Award in clinical studies. Spine (Phila Pa 1976) (2002) 2.70
Adenovirus-mediated in vivo gene transfer and expression in normal rat liver. Nat Genet (1992) 2.63
Gene therapy clinical trials worldwide to 2012 - an update. J Gene Med (2013) 2.57
Characterization of the distinct orthotopic bone-forming activity of 14 BMPs using recombinant adenovirus-mediated gene delivery. Gene Ther (2004) 2.55
Genetic content and evolution of adenoviruses. J Gen Virol (2003) 2.54
Oncolytic viruses in cancer therapy. Cancer Lett (2007) 2.45
Immune responses to viral antigens versus transgene product in the elimination of recombinant adenovirus-infected hepatocytes in vivo. Gene Ther (1996) 2.43
Epigenetic reprogramming by adenovirus e1a. Science (2008) 2.38
Distinct roles of bone morphogenetic proteins in osteogenic differentiation of mesenchymal stem cells. J Orthop Res (2007) 2.26
Prime-boost vectored malaria vaccines: progress and prospects. Hum Vaccin (2010) 2.12
Expanding the Biologist's Toolkit with CRISPR-Cas9. Mol Cell (2015) 2.11
Recombinational construction in Escherichia coli of infectious adenoviral genomes. Proc Natl Acad Sci U S A (1997) 2.10
A Monovalent Chimpanzee Adenovirus Ebola Vaccine Boosted with MVA. N Engl J Med (2015) 2.10
The future of cancer treatment: immunomodulation, CARs and combination immunotherapy. Nat Rev Clin Oncol (2016) 2.09
Chimpanzee adenovirus vaccine generates acute and durable protective immunity against ebolavirus challenge. Nat Med (2014) 2.09
Progress and prospects: immune responses to viral vectors. Gene Ther (2009) 2.05
The effect of regional gene therapy with bone morphogenetic protein-2-producing bone-marrow cells on the repair of segmental femoral defects in rats. J Bone Joint Surg Am (1999) 2.00
Efficient construction of a recombinant adenovirus vector by an improved in vitro ligation method. Hum Gene Ther (1998) 1.99
Gene delivery by lentivirus vectors. Mol Biotechnol (2007) 1.98
Mutational analysis of the N-terminal DNA-binding domain of sleeping beauty transposase: critical residues for DNA binding and hyperactivity in mammalian cells. Mol Cell Biol (2004) 1.97
Several rAAV vectors efficiently cross the blood-brain barrier and transduce neurons and astrocytes in the neonatal mouse central nervous system. Mol Ther (2011) 1.96
New insights on adenovirus as vaccine vectors. Mol Ther (2009) 1.90
Recent advances in lentiviral vector development and applications. Mol Ther (2010) 1.89
Growth factor regulation of fracture repair. J Bone Miner Res (1999) 1.88
Regulation of osteogenic differentiation during skeletal development. Front Biosci (2008) 1.88
A comprehensive analysis of the dual roles of BMPs in regulating adipogenic and osteogenic differentiation of mesenchymal progenitor cells. Stem Cells Dev (2009) 1.87
Virus treatment questioned after gene therapy death. Nature (1999) 1.81
A phase I study of an adeno-associated virus-CFTR gene vector in adult CF patients with mild lung disease. Hum Gene Ther (1996) 1.80
Prostate attenuated replication competent adenovirus (ARCA) CN706: a selective cytotoxic for prostate-specific antigen-positive prostate cancer cells. Cancer Res (1997) 1.79
Vaccine to confer to nonhuman primates complete protection against multistrain Ebola and Marburg virus infections. Clin Vaccine Immunol (2008) 1.78
A phase I trial of intravenous CG7870, a replication-selective, prostate-specific antigen-targeted oncolytic adenovirus, for the treatment of hormone-refractory, metastatic prostate cancer. Mol Ther (2006) 1.74
Current status of gendicine in China: recombinant human Ad-p53 agent for treatment of cancers. Hum Gene Ther (2005) 1.73
BMP-14 gene therapy increases tendon tensile strength in a rat model of Achilles tendon injury. J Bone Joint Surg Am (2007) 1.70
Bone morphogenetic proteins: from basic studies to clinical approaches. Bone (1998) 1.69
Oncolytic adenovirus coding for granulocyte macrophage colony-stimulating factor induces antitumoral immunity in cancer patients. Cancer Res (2010) 1.69
A phase I trial of CV706, a replication-competent, PSA selective oncolytic adenovirus, for the treatment of locally recurrent prostate cancer following radiation therapy. Cancer Res (2001) 1.68
Chimpanzee adenovirus- and MVA-vectored respiratory syncytial virus vaccine is safe and immunogenic in adults. Sci Transl Med (2015) 1.67
A replication defective recombinant Ad5 vaccine expressing Ebola virus GP is safe and immunogenic in healthy adults. Vaccine (2010) 1.66
Comparative analysis of transposable element vector systems in human cells. Mol Ther (2010) 1.66
Retroviral vector integration occurs in preferred genomic targets of human bone marrow-repopulating cells. Blood (2002) 1.65
Overview of STEP and Phambili trial results: two phase IIb test-of-concept studies investigating the efficacy of MRK adenovirus type 5 gag/pol/nef subtype B HIV vaccine. Curr Opin HIV AIDS (2010) 1.63
Clinical trials with oncolytic adenovirus in China. Curr Cancer Drug Targets (2007) 1.62
Optimization of the helper-dependent adenovirus system for production and potency in vivo. Proc Natl Acad Sci U S A (2000) 1.62
Gene therapy for malignant glioma: current clinical status. Mol Ther (2005) 1.61
A phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer. Clin Cancer Res (2000) 1.59
Insulin-like growth factor 2 (IGF-2) potentiates BMP-9-induced osteogenic differentiation and bone formation. J Bone Miner Res (2010) 1.58
Safety and immunogenicity of a chimpanzee adenovirus-vectored Ebola vaccine in healthy adults: a randomised, double-blind, placebo-controlled, dose-finding, phase 1/2a study. Lancet Infect Dis (2015) 1.57
Selective replication and oncolysis in p53 mutant tumors with ONYX-015, an E1B-55kD gene-deleted adenovirus, in patients with advanced head and neck cancer: a phase II trial. Cancer Res (2000) 1.55
Adenovirus p53 gene therapy. Expert Opin Biol Ther (2006) 1.49
Lentiviral vectors: basic to translational. Biochem J (2012) 1.49
Intravascular adenoviral agents in cancer patients: lessons from clinical trials. Cancer Gene Ther (2002) 1.49
Gene therapy: the first decade. Trends Biotechnol (2000) 1.46
Viral and nonviral delivery systems for gene delivery. Adv Biomed Res (2012) 1.42
Viral vectors for gene transfer: a review of their use in the treatment of human diseases. Drugs (2000) 1.42
Regulatable gutless adenovirus vectors sustain inducible transgene expression in the brain in the presence of an immune response against adenoviruses. J Virol (2006) 1.41
Global CNS transduction of adult mice by intravenously delivered rAAVrh.8 and rAAVrh.10 and nonhuman primates by rAAVrh.10. Mol Ther (2014) 1.41
Transposons for gene therapy! Curr Gene Ther (2006) 1.40
Herpes vector-mediated expression of proenkephalin reduces bone cancer pain. Ann Neurol (2002) 1.40
Bone Morphogenetic Protein (BMP) signaling in development and human diseases. Genes Dis (2014) 1.27
The versatile functions of Sox9 in development, stem cells, and human diseases. Genes Dis (2014) 0.98
Wnt and BMP Signaling Crosstalk in Regulating Dental Stem Cells: Implications in Dental Tissue Engineering. Genes Dis (2016) 0.76
Damage control: Harnessing prostaglandin E2 as a potential healing factor of tissue injuries. Genes Dis (2015) 0.76
Insider information: Testing cancer drug sensitivity for personalized therapy. Genes Dis (2015) 0.76
An NgAgo tool for genome editing: did CRISPR/Cas9 just find a competitor? Genes Dis (2016) 0.75
Transition to resistance: An unexpected role of the EMT in cancer chemoresistance. Genes Dis (2016) 0.75